EMA approves 14 medicines, rejects Alzheimer’s drug Leqembi

euractiv.com

The European Medicines Agency (EMA) has rejected the Alzheimer’s drug Leqembi (lecanemab) due to concerns over brain swelling and bleeding risks, despite its approval in the US, Japan, and China. The EMA recommended 14 new medicines, including six biosimilars, and extended indications for 11 others, such as Wegovy, which may reduce cardiovascular death risk by 15%.


With a significance score of 4.4, this news ranks in the top 3.4% of today's 28502 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


EMA approves 14 medicines, rejects Alzheimer’s drug Leqembi | News Minimalist